De ontwikkeling van een keuzehulp voor patiënten bij de behandeling van diabetes en bijkomende risico's.

Gepubliceerd: 10-08-2009 Laatst bijgewerkt: 18-08-2022

The aim of this study is to develop and evaluate a patient-oriented treatment decision aid (PTDA) focussing on shared goal-setting and decision making, which is tailored to the needs and capacities of a heterogeneous group of patients with type 2...

Ethische beoordeling	Positief advies
Status	Werving nog niet gestart
Type aandoening	-
Onderzoekstype	Interventie onderzoek

Samenvatting

ID

NL-OMON27858

Bron
Nationaal Trial Register

Verkorte titel
PORTDA-diab

Aandoening

Diabetes Mellitus Therapy/ Diabetes Mellitus Behandeling
Computer-Assisted Decision Making/ Computer-ondersteund Beslissen
Patient Education/ Patient Informatie
Guideline Adherence/ Richtlijn Adherentie

Ondersteuning

Primaire sponsor: University Medical Center Groningen
Overige ondersteuning: ZonMW

Onderzoeksproduct en/of interventie

Uitkomstmaten

Primaire uitkomstmaten

Patient empowerment measured with Diabetes Empowerment Scale (overall and subscale ‘Setting and Achieving Goals’).

Toelichting onderzoek

Achtergrond van het onderzoek

A newly developed patient oriented treatment decision aid (PTDA) will be evaluated in a randomized pre-postintervention study using a 2-by-2 factorial intervention design with a control group. The PTDA offers personalized information on possible treatment options and outcomes. The information is intended to empower the patients in taking a proactive role in their disease management. It will be offered to the patients before a scheduled year visit for diabetes management, and can then be used during this visit and further follow-up visits with the general practitioner.

Based on results of (inter)national research regarding shared goal-setting and decision making among elderly and patients with diabetes, two formats of the PTDA will be developed. The first will use the traditional clinical approach for presenting risks. The second will also provide information formulated from a patient perspective, as described in several qualitative studies. Both formats can be offered in a computer-based and a paper-based version. The information will be generated automatically using routinely registered information from the electronic medical records in addition to evidence-based information on diabetes treatment and outcomes. The 4 different versions will be evaluated in a trial with 450 patients from 20 general practices. Patients will be recruited in practices that participate in the GIANTT project. Practices will be randomly allocated to use the paper or the computer version of the PTDA and receive training on how to work with the PTDA. Within the practices, patients will be randomized to receive information from the clinical perspective or also from the patient perspective. Pre- and postintervention measurements will be conducted, where patients will receive questionnaires. Data for the other (secondary) outcomes will be collected using existing automated extractions from electronic medical records. Post-intervention questions on feasibility will be collected for a sample of visits.

Doel van het onderzoek

The aim of this study is to develop and evaluate a patient-oriented treatment decision aid (PTDA) focussing on shared goal-setting and decision making, which is tailored to the needs and capacities of a heterogeneous group of patients with type 2 diabetes. As part of the development process, the impact of different presentation formats and methods will be evaluated. Research questions are:

1. What is the impact of providing such personalized information on patient empowerment, negative emotions, beliefs about treatment options, satisfaction with care, and on treatment decisions and outcomes?

2. To what extent are effects at patient level modified by the presentation format (using a clinical or patient perspective) and presentation medium (paper or computer-based)?

3. What is the feasibility of implementing the decision support tool in daily practice?

Onderzoeksopzet

Questionnaires data will be collected around one month before and three months after the intervention, using the following instruments:

1. Diabetes Empowerment Scale DES, i.e. overall-DES-scale and subscale ‘Setting and Achieving Goals’;
2. Patients' Evaluation of the Quality of Diabetes Care PEQ-D;

3. Beliefs about Medication Questionnaire BMQ;

4. Problem Areas in Diabetes Scale PAID.

Preintervention and postintervention data will be collected from medical records using the GIANTT database (www.Giantt.nl) in the year before and after the intervention to assess differences in percentages of patients with (intensified) antihypertensive treatment after insufficiently controlled blood pressure levels, of patients with (intensified) glucose-lowering treatment after insufficiently controlled HbA1c-levels, of patients treated with lipid-lowering drugs, of patients with (micro)albuminuria treated with a RAAS inhibitor, and changes in predicted absolute 10-year coronary heart disease risk (UKPDS risk engine calculation).

Onderzoeksproduct en/of interventie

The patient-oriented treatment decision aid offers personalized information on possible treatment options and outcomes. The information is intended to empower the patients in taking a proactive role in their disease management. It will be offered to the patients before a scheduled year visit for diabetes management, and can then be used during this visit and further follow-up visits with the general practitioner.

Four different versions will be used, varying in presentation format (clinical/ patient perspective) and presentation medium (paper/computer-based). The four intervention groups will thus receive information presented from:

1. Clinical perspective on paper;

2. Clinical and patient perspective on paper;

3. Clinical perspective on computer;

4. Clinical and patient perspective on computer.

The control group will receive care/information as usual.

Contactpersonen

Publiek

ector F/Department of Clinical Pharmacology, University Medical Center Groningen, PO Box 196,
P. Denig
ector F/Department of Clinical Pharmacology, University Medical Center Groningen, PO Box 196,
Groningen 9700 AD
The Netherlands
+31503633205

Wetenschappelijk

ector F/Department of Clinical Pharmacology, University Medical Center Groningen, PO Box 196,
P. Denig
ector F/Department of Clinical Pharmacology, University Medical Center Groningen, PO Box 196,
Groningen 9700 AD
The Netherlands
+31503633205

Deelname eisen

Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)

Patients with type 2 diabetes managed by GPs.

Belangrijkste redenen om niet deel te kunnen nemen

(Exclusiecriteria)

1. Dementia;

2. Known cognitive deficits;

3. Not able to read Dutch;

4. Terminal illness;

5. Previous stroke or heart disease;

6. Above 65 years of age at diagnosis diabetes.

Onderzoeksopzet

Opzet

Type:	Interventie onderzoek
Onderzoeksmodel:	Factorieel
Toewijzing:	Gerandomiseerd
Blindering:	Open / niet geblindeerd
Controle:	Placebo

Deelname

Nederland

Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-02-2010
Aantal proefpersonen:	450
Type:	Verwachte startdatum

Ethische beoordeling

Positief advies

Datum:	10-08-2009
Soort:	Eerste indiening

Registraties

Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

In overige registers

Register	ID
NTR-new	NL1832
NTR-old	NTR1942
Ander register	ABR/ZonMW : 29042/project 300020006
ISRCTN	ISRCTN wordt niet meer aangevraagd.

Resultaten

Samenvatting resultaten
N/A